# GENECKER

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genecker

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.genecker.com/
- Total disclosed funding: $18M
- Latest round: Series C (Dec 3, 2025)
- Investors on record: 7

## About

Based in Seoul, South Korea, and founded in 2017, Jin Seaker Co., Ltd., d.b.a. GeneCker is a biotechnology company that conducts tests for cancer genomes, rare disease genomes, prenatal genomes, and individual genomes in order to provide personalized diagnosis, treatment, and health management methods. In December 2025, GENECKER raised approximately KRW 15 billion in series C funding from new investors Aju Pharm Co., Ltd. and A Ventures. Other unspecified investors also participated in the round. As of May 2025, Seong-hyeok Ye is the CEO of GeneCker.

The company provides cloning services, such as gcFusion cloning (Insertion/Deletion/Domain Exchange), and gcFusion cloning (Mutagenesis) that allow plasmids to be produced in the desired structure; next generation sequencing, which includes mutation analysis service and illumine sequencing; and protein purification, a protein isolation and purification service by selecting optimal expression conditions with His tag, extensively applied tags for recombinant protein expression and purification. In addition, GeneCker develops CRISPR, a genome-testing platform.

The company will use the 2025 funding to improve its multi-cancer diagnosis and monitoring solutions.

## Funding rounds

- Series C, Dec 3, 2025, $10M — A Ventures, Aju Pharm Co., Ltd.
- Series B, May 4, 2022, $6.3M — Covent Capital Partners, UTC Investment, Premier Partners, Magna Investment, Friend Investment Partners
- Series A, Oct 1, 2019, $1.7M — Magna Investment, Friend Investment Partners

## Investors

- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A, Series B
- Friend Investment Partners (https://capitalatlas.ai/funds/friend-investment-partners) — Series A, Series B
- Covent Capital Partners — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series B
- A Ventures — Series C
- Aju Pharm Co., Ltd. — Series C